The role of topiceuticals in cancer pain

Paisley, Peter; Serpell, Michael

doi:10.1097/spc.0000000000000271

Cited by 6 publications

(4 citation statements)

References 35 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer patients, where organ failures (kidney or liver impairment) may limit the use of systemic drugs, their use is particularly advantageous. However, data on LNP in MM patients are still lacking [88].…”

Section: Herpetic and Post-herpetic Neuralgiamentioning

confidence: 99%

Pain Management in Patients with Multiple Myeloma: An Update

Coluzzi

Rolke

Mercadante

2019

Cancers

View full text Add to dashboard Cite

Most patients with multiple myeloma (MM) suffer from chronic pain at every stage of the natural disease process. This review focuses on the most common causes of chronic pain in MM patients: (1) pain from myeloma bone disease (MBD); (2) chemotherapy-induced peripheral neuropathy as a possible consequence of proteasome inhibitor therapy (i.e., bortezomib-induced); (3) post-herpetic neuralgia as a possible complication of varicella zoster virus reactivation because of post-transplantation immunodepression; and (4) pain in cancer survivors, with increasing numbers due to the success of antiblastic treatments, which have significantly improved overall survival and quality of life. In this review, non-pain specialists will find an overview including a detailed description of physiopathological mechanisms underlying central sensitization and pain chronification in bone pain, the rationale for the correct use of analgesics and invasive techniques in different pain syndromes, and the most recent recommendations published on these topics. The ultimate target of this review was to underlie that different types of pain can be observed in MM patients, and highlight that only after an accurate pain assessment, clinical examination, and pain classification, can pain be safely and effectively addressed by selecting the right analgesic option for the right patient.

show abstract

Section: Herpetic and Post-herpetic Neuralgiamentioning

confidence: 99%

Pain Management in Patients with Multiple Myeloma: An Update

Coluzzi

Rolke

Mercadante

2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Potential topiceuticals which may be applied to areas of focal pain include 5% lidocaine patches, 2% menthol in aqueous cream, clonidine, ketamine and topical tricyclic antidepressants. 146 Large, well conducted RCTs supporting the use of Lidocaine patches are lacking. 147 However the patches may in some circumstances demonstrate equivalence to systemic anti-neuropathic agents with superior tolerability.…”

Section: Pharmacological Management Opioidsmentioning

confidence: 99%

Pain in cancer survivors; filling in the gaps

Brown

Farquhar-Smith

2017

British Journal of Anaesthesia

View full text Add to dashboard Cite

Cancer survivorship represents a growing clinical challenge for pain clinicians. The population of cancer survivors is rapidly expanding and many of these patients experience pain as a sequelae of their disease and its treatment. The features, pathophysiology and natural history of some painful conditions observed in cancer survivors, such as direct tumour effects, cancer induced bone pain (CIBP) or chronic post-surgical pain have received extensive exposure elsewhere in the literature. In this narrative review, we attempt to 'fill in the gaps' in the knowledge, by providing a succinct outline of a range of less well known pain states encountered in the cancer survivor population. These include neuropathies as a result of graft versus host disease (GVHD), novel chemotherapeutic agents and monoclonal antibodies (mAb), and radiation induced pain states. The increasing prevalence of visceral post-surgical pain and aromatase inhibitor-induced arthralgia (AIA) is also detailed. Additionally an overview of suggested approaches to the assessment of pain in cancer survivors is provided and potential treatment strategies, with a focus on novel approaches are discussed.

show abstract

“…6,7 Besides oral opioids and other analgesics, topical preparations appear effective, 8 can be targeted at the pain area, and may avoid the adverse effects of systemic medications. 9,10 Adjunctive and non-pharmacologic interventions, including acupuncture and other complementary therapies, can also be considered. [11][12][13][14][15][16][17] Nevertheless, it has been suggested that new pharmaceuticals are needed.…”

Section: Introductionmentioning

confidence: 99%

“…23,24 Their greater use has been proposed, particularly for localized neuropathic pain associated with malignancy. 9 A Cochrane review on topical capsaicin, a natural product from plants in the Capsicum genus, found evidence of effectiveness for chronic neuropathic pain. 8 In a recent review, evidence was found for multiple topical analgesics, although this included case series and case reports.…”

Section: Introductionmentioning

confidence: 99%

Topical Traditional Chinese Medicines for Cancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Liu,

May,

Hyde

et al. 2023

Integr Cancer Ther

View full text Add to dashboard Cite

Background and objectives: Safe and effective management of cancer-related pain is a worldwide challenge. In the search for treatment options, natural products used in Chinese herbal medicines (CHMs) have received attention in clinical studies for their effects on cancer-related pain. The objective of this systematic review is to evaluate the clinical evidence for topically applied CHMs as adjunctive treatments for cancer pain management. Methods: Nine biomedical databases and 4 clinical trial registries were searched for randomized-controlled trials (RCTs) that reported measures of pain and/or quality of life. Risk of bias was assessed using the Cochrane tool. Meta-analysis employed mean difference (MD) with 95% confidence intervals (random effects). Results: Twenty (20) RCTs (1636 participants) met the inclusion criteria. Meta-analyses were grouped based on the comparisons and outcome measures. For pain intensity, there was a greater reduction in the topical CHM group versus placebo (MD −0.72 [−1.04, −0.40]), no difference when compared to tramadol (MD −0.15 [−0.38, 0.08]), and a greater reduction when topical CHMs were combined with conventional analgesic medications (MD −0.67 [−0.93, −0.40]). Analgesic onset time was reduced in the CHM group compared to tramadol (MD −26.02 [−27.57, −24.47] minutes), and for CHMs combined with conventional medications (MD −19.17 [−21.83, −16.52] minutes). When CHMs were combined with analgesic medications, improvements were found for duration of analgesia (MD 1.65 [0.78, 2.51] hours), analgesic maintenance dose (MD −31.72 [−50.43, −13.01] milligrams/day), and quality of life. Conclusion: Addition of topical CHMs to conventional analgesic medications was associated with improved outcomes for pain intensity, some other pain-related outcomes, and measures of quality of life. Limitations included methodological issues in some studies and considerable heterogeneity in some pooled results.

show abstract

The role of topiceuticals in cancer pain

Cited by 6 publications

References 35 publications

Pain Management in Patients with Multiple Myeloma: An Update

Pain Management in Patients with Multiple Myeloma: An Update

Pain in cancer survivors; filling in the gaps

Topical Traditional Chinese Medicines for Cancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About